3 results
Approved WMOCompleted
•To evaluate the efficacy of ASP8302 compared with placebo in subjects with Underactive Bladder (UAB)•To investigate the safety and tolerability of ASP8302 compared with placebo in subjects with UAB•To investigate the pharmacokinetics of ASP8302 in…
Approved WMOPending
To find the maximum tolerated dose of glass yttrium-90 (90Y) microspheres (TheraSphere®), when combined with DEBIRI in patients with liver-dominant colorectal liver metastases (CRLM).
Approved WMOPending
The primary objective is to determine the effect of Transvamix on the pain quality item *unpleasantness*, relative to placebo. Secondary objectives include the assessment of general pain qualities, pain self-efficacy, general pain and pruritus…